The company will carry out a reverse stock split in a ratio of 1:125. The share will be traded under new ISIN code with effect from Oct 17, 2025. The order book will not change.
| Short name: | XBRANE |
| Terms: | Reverse split: 1:125 |
| Current ISIN: | SE0007789409 |
| Last day of trading with current ISIN code: | Oct 16, 2025 |
| New ISIN code: | SE0026598583 |
| First day of trading with new ISIN code: | Oct 17, 2025 |
Nasdaq Stockholm AB, Issuer Surveillance, dl-ilasto@nasdaq.com, +46 8 405 7280
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14:05 | Reverse split and Change of ISIN for Xbrane Biopharma AB | The company will carry out a reverse stock split in a ratio of 1:125. The share will be traded under new ISIN code with effect from Oct 17, 2025. The order book will not change.
Short... ► Artikel lesen | |
| Mi | Xbrane Biopharma AB: Record date for reverse share split in Xbrane Biopharma AB | At the Extra General Meeting of Xbrane Biopharma AB ("Xbrane" or the "Company") held on 13 October 2025, it was resolved to carry out a reverse share split in the ratio 1:125, whereby 125 existing shares... ► Artikel lesen | |
| Mo | Xbrane Biopharma AB: Announcement from extra general meeting in Xbrane Biopharma AB | Today on 13 October 2025 the extra general meeting of Xbrane Biopharma AB (the "Company") was held and the following resolutions were passed by the meeting.
Amendments of the articles of associationThe... ► Artikel lesen | |
| 01.09. | Xbrane Biopharma Q2 2025 slides reveal Ximluci market share gains amid financial restructuring | ||
| 01.09. | Xbrane Q2 2025: Ximluci gewinnt Marktanteile |
